Intra-Cellular Therapies to Present at the 2016 RBC Capital Markets’ Healthcare Conference

NEW YORK, Feb. 16, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ("CNS") disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 2016 RBC Capital Markets’ Healthcare Conference. The presentation is scheduled for Tuesday, February 23rd, 2016 at 11:00 am EST.

The live and archived webcast can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.

About Intra-Cellular Therapies

Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The Company is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in dementia, depression and other neuropsychiatric and neurological disorders. ITI-007, a first-in-class molecule, is in Phase 3 clinical development for the treatment of schizophrenia and bipolar depression. The Company is also utilizing its phosphodiesterase platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders.

Contact:
Juan Sanchez, M.D. 
Vice President 
Corporate Communications and Investor Relations of Intra-Cellular Therapies, Inc. 
Phone:  212-923-3344

Burns McClellan, Inc.
Lisa Burns 
Justin Jackson (Media)
[email protected]
212-213-0006

Source: Intra-Cellular Therapies, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Intra-Cellular Therapies (ITCI) PT Raised to $107 at Canaccord Genuity
• Adevinta (ASA) publishes its 2023 Annual Report
• Intra-Cellular Therapies (ITCI) PT Raised to $96 at Mizuho